Patent ID: 8703787

Claim:
A method for treating EML4-ALK + mediated non-small cell lung cancer that is optionally resistant to crizotinib, comprising administering to a cell or subject a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein R 1 is halo; R 2 is H; or wherein R 1 and R 2 together with the carbon atoms to which they are attached form a 5-6 membered heteroaryl comprising 1-2 heteroatoms selected from N, O and S; R 3 is SO 2 R 7 wherein R 7 is C 1-6 alkyl; R 4 is C 1-6 alkoxy; R 5 is piperidinyl optionally substituted with C 1-6 alkyl; R 6 is C 1-6 alkyl; or R 5 and R 6 together with the carbon atoms to which they are attached form a 5-6 membered heterocyclic ring comprising having 1-2 heteroatoms selected from N, O and S.